Possible Therapy for Platinum-Resistant Ovarian Cancer, CRLX101, Put on Fast Track by FDA

Possible Therapy for Platinum-Resistant Ovarian Cancer, CRLX101, Put on Fast Track by FDA
Cerulean Pharma announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its nanoparticle-drug conjugate (NDC) CRLX101, used in combination with paclitaxel, to treat platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer patients. “We appreciate the FDA’s acknowledgement of CRLX101’s potential in an area of significant unmet medical need,” Christopher Guiffre, president and chief executive officer of Cerulean,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *